258 related articles for article (PubMed ID: 8843305)
1. Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli to 12 beta-lactam agents and combinations with beta-lactamase inhibitors.
Tajada P; Gomez-Graces JL; Alós JI; Balas D; Cogollos R
Antimicrob Agents Chemother; 1996 Aug; 40(8):1924-5. PubMed ID: 8843305
[TBL] [Abstract][Full Text] [Related]
2. Susceptibilities of beta-lactamase-positive and -negative strains of Campylobacter coli to beta-lactam agents.
Lachance N; Gaudreau C; Lamothe F; Turgeon F
Antimicrob Agents Chemother; 1993 May; 37(5):1174-6. PubMed ID: 8390812
[TBL] [Abstract][Full Text] [Related]
3. Beta-lactam resistance in Campylobacter coli and Campylobacter jejuni chicken isolates and the association between bla
Casagrande Proietti P; Guelfi G; Bellucci S; De Luca S; Di Gregorio S; Pieramati C; Franciosini MP
Vet Microbiol; 2020 Feb; 241():108553. PubMed ID: 31928700
[TBL] [Abstract][Full Text] [Related]
4. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
Piddock LJ; Jin YF; Turner HL
J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
[TBL] [Abstract][Full Text] [Related]
5. Role of the beta-lactamase of Campylobacter jejuni in resistance to beta-lactam agents.
Lachance N; Gaudreau C; Lamothe F; Larivière LA
Antimicrob Agents Chemother; 1991 May; 35(5):813-8. PubMed ID: 1854162
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
Higgins PG; Wisplinghoff H; Stefanik D; Seifert H
Antimicrob Agents Chemother; 2004 May; 48(5):1586-92. PubMed ID: 15105109
[TBL] [Abstract][Full Text] [Related]
7. Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
Griggs DJ; Peake L; Johnson MM; Ghori S; Mott A; Piddock LJ
Antimicrob Agents Chemother; 2009 Aug; 53(8):3357-64. PubMed ID: 19506058
[TBL] [Abstract][Full Text] [Related]
8. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility of Campylobacter jejuni to 27 antimicrobial agents and various combinations of beta-lactams with clavulanic acid or sulbactam.
Van der Auwera P; Scorneaux B
Antimicrob Agents Chemother; 1985 Jul; 28(1):37-40. PubMed ID: 2994557
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
Gatermann S; Marre R
Infection; 1991; 19(2):106-9. PubMed ID: 1646771
[TBL] [Abstract][Full Text] [Related]
11. Evolution of beta-lactamase inhibitors.
Rolinson GN
Rev Infect Dis; 1991; 13 Suppl 9():S727-32. PubMed ID: 1656513
[TBL] [Abstract][Full Text] [Related]
12. In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents.
Betriu C; Sánchez A; Gómez M; Palau ML; Picazo JJ
J Antimicrob Chemother; 1999 Jan; 43(1):133-6. PubMed ID: 10381111
[TBL] [Abstract][Full Text] [Related]
13. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
Giakkoupi P; Tzelepi E; Legakis NJ; Tzouvelekis LS
J Antimicrob Chemother; 1999 Jan; 43(1):23-9. PubMed ID: 10381097
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of beta-lactamase inhibitors against clinical isolates of Acinetobacter species.
Suh B; Shapiro T; Jones R; Satishchandran V; Truant AL
Diagn Microbiol Infect Dis; 1995 Feb; 21(2):111-4. PubMed ID: 7628190
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteria.
Kitzis MD; Ferré B; Coutrot A; Acar JF; Gutmann L
Eur J Clin Microbiol Infect Dis; 1989 Sep; 8(9):783-8. PubMed ID: 2556277
[TBL] [Abstract][Full Text] [Related]
17. Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications.
Sutherland R
Infection; 1995; 23(4):191-200. PubMed ID: 8522374
[No Abstract] [Full Text] [Related]
18. [The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro].
Blahová J; Hupková M; Krcméry V
Cas Lek Cesk; 1995 Sep; 134(17):558-61. PubMed ID: 7553760
[TBL] [Abstract][Full Text] [Related]
19. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Nomura S; Hanaki H; Nagayama A
J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
[TBL] [Abstract][Full Text] [Related]
20. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
Bonomo RA; Rudin SA; Shlaes DM
FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
